Literature DB >> 10547388

Tamoxifen prevention of breast cancer: an instance of the fingerpost.

S M Lippman1, P H Brown.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547388     DOI: 10.1093/jnci/91.21.1809

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

Review 1.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump.

Authors:  Rebecca Taylor; Kenneth Taguchi
Journal:  Ann Fam Med       Date:  2005 May-Jun       Impact factor: 5.166

3.  JNCI and cancer prevention.

Authors:  Barbara K Dunn; Sharmistha Ghosh; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2015-02-24       Impact factor: 13.506

4.  Assessment of common risk factors and validation of the Gail model for breast cancer: A hospital-based study from Western India.

Authors:  Naveen Kumar; Vinit Singh; Garima Mehta
Journal:  Tzu Chi Med J       Date:  2020-04-10

Review 5.  Cancer Prevention: Obstacles, Challenges and the Road Ahead.

Authors:  Frank L Meyskens; Hasan Mukhtar; Cheryl L Rock; Jack Cuzick; Thomas W Kensler; Chung S Yang; Scott D Ramsey; Scott M Lippman; David S Alberts
Journal:  J Natl Cancer Inst       Date:  2015-11-07       Impact factor: 13.506

6.  First do no harm: extending the debate on the provision of preventive tamoxifen.

Authors:  B P Will; K M Nobrega; J M Berthelot; W Flanagan; M C Wolfson; D M Logan; W K Evans
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

Review 7.  Raloxifene as a treatment option for viral infections.

Authors:  Subin Hong; JuOae Chang; Kwiwan Jeong; Wonsik Lee
Journal:  J Microbiol       Date:  2021-02-01       Impact factor: 3.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.